Academic Journal
Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation.
| Τίτλος: | Live attenuated varicella-zoster virus vaccine does not induce HIV target cell activation. |
|---|---|
| Συγγραφείς: | Perciani, CT, Farah, B, Kaul, R, Ostrowski, MA, Mahmud, SM, Anzala, O, Jaoko, W, KAVI-ICR Team, MacDonald, KS |
| Στοιχεία εκδότη: | BMC |
| Έτος έκδοσης: | 2019 |
| Συλλογή: | University of Nairobi Digital Repository |
| Θεματικοί όροι: | AIDS vaccine, AIDS/HIV, Cytokines, T cells, Vaccines |
| Περιγραφή: | BACKGROUND: Varicella-zoster virus (VZV) is under consideration as a promising recombinant viral vector to deliver foreign antigens including HIV. However, new vectors have come under increased scrutiny, since trials with adenovirus serotype 5-vectored (Ad5-vectored) HIV vaccine demonstrated increased HIV risk in individuals with pre-immunity to the vector that was thought to be associated with mucosal immune activation (IA). Therefore, given the prospect of developing an HIV/VZV chimeric vaccine, it is particularly important to define the impact of VZV vaccination on IA. METHODS: Healthy VZV-seropositive Kenyan women (n = 44) were immunized with high-dose live attenuated VZV vaccine, and we assessed the expression on CD4+ T cells isolated from blood, cervix, and rectum of IA markers including CD38 and HLA-DR and of markers of cell migration and tissue retention, as well as the concentration of genital and intestinal cytokines. A delayed-start group (n = 22) was used to control for natural variations in these parameters. RESULTS: Although immunogenic, VZV vaccination did not result in significant difference in the frequency of cervical activated (HLA-DR+CD38+) CD4+ T cells (median 1.61%, IQR 0.93%-2.76%) at 12 weeks after vaccination when compared with baseline (median 1.58%, IQR 0.75%-3.04%), the primary outcome for this study. VZV vaccination also had no measurable effect on any of the IA parameters at 4, 8, and 12 weeks after vaccination. CONCLUSION: This study provides the first evidence to our knowledge about the effects of VZV vaccination on human mucosal IA status and supports further evaluation of VZV as a potential vector for an HIV vaccine. |
| Τύπος εγγράφου: | article in journal/newspaper |
| Περιγραφή αρχείου: | application/pdf |
| Γλώσσα: | English |
| Relation: | https://www.ncbi.nlm.nih.gov/pubmed/30511963; http://erepository.uonbi.ac.ke/handle/11295/106532 |
| Διαθεσιμότητα: | https://www.ncbi.nlm.nih.gov/pubmed/30511963 http://erepository.uonbi.ac.ke/handle/11295/106532 |
| Αριθμός Καταχώρησης: | edsbas.686E5322 |
| Βάση Δεδομένων: | BASE |
| Η περιγραφή δεν είναι διαθέσιμη |